INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 08/18/23
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against TG Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 08/08/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 08/05/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against TG Therapeutics, Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the FirmAccesswire • 08/03/23
Sales Of TG Therapeutics' New Product Doubled — Here's Why Shares HalvedInvestors Business Daily • 08/01/23
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/01/23
TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)GlobeNewsWire • 08/01/23
TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business UpdateGlobeNewsWire • 07/31/23
Down -12.63% in 4 Weeks, Here's Why You Should You Buy the Dip in TG Therapeutics (TGTX)Zacks Investment Research • 07/24/23
How Roche Just Cut Top 1% Biotech Stock TG Therapeutics Down A PegInvestors Business Daily • 07/13/23
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual MeetingGlobeNewsWire • 06/02/23
TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in AdultsGlobeNewsWire • 06/01/23
TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual MeetingGlobeNewsWire • 05/31/23
TG Therapeutics to Participate in the Bank of America Securities 2023 Health Care ConferenceGlobeNewsWire • 05/04/23
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move TodayThe Motley Fool • 05/01/23